Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Documenti analoghi

• Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration
  di: Zubeyir Salis, et al.
  Pubblicazione: (2026)
• Genetically Proxied Interleukin‐13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization Study
  di: Sizheng Steven Zhao, et al.
  Pubblicazione: (2024)
• Asymptotic Analysis and Practical Evaluation of Jump Rate Estimators in Piecewise-Deterministic Markov Processes
  di: Azaïs, Romain, et al.
  Pubblicazione: (2025)
• Comparing DAPSA, DAPSA28, and DAS28‐CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
  di: Louise Linde, et al.
  Pubblicazione: (2024)
• PÈRES ET CHEIKHS. RAPPORTS D'ÂGE ET D'AUTORITÉ RELIGIEUSE AU CAIRE
  di: Aymon Kreil
  Pubblicazione: (2008)